{"name":"Veru Inc.","slug":"veru-inc","ticker":"","exchange":"","domain":"","description":"Veru Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for the treatment of cancer and urological diseases. The company has a diverse pipeline with several drugs in various stages of development, including phase 3 trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":16296958,"revenueGrowth":-58.6,"grossMargin":0,"rdSpend":15588185,"netIncome":-22726279,"cash":29835719,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Enzalutamide, Abiraterone","genericName":"Enzalutamide, Abiraterone","slug":"enzalutamide-abiraterone","indication":"Metastatic castration-resistant prostate cancer (mCRPC)","status":"phase_3"}]}],"pipeline":[{"name":"Enzalutamide, Abiraterone","genericName":"Enzalutamide, Abiraterone","slug":"enzalutamide-abiraterone","phase":"phase_3","mechanism":"This combination of an androgen receptor antagonist (enzalutamide) and a CYP17A1 inhibitor (abiraterone) blocks testosterone production and androgen signaling to treat hormone-sensitive prostate cancer.","indications":["Metastatic castration-resistant prostate cancer (mCRPC)","Metastatic hormone-sensitive prostate cancer (mHSPC)"],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2026-03-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-11","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2026-02-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxPb3BVYVVSNnRlRFpQRE5raEJ0VnJoanBVd0ZVdDlNaDhPLW5CVDdqdERVUmNDbTBpRjZnRjJyNW10dFVaWmliMjIyZFV4Z2RaWm0yQXpCTmZGd2dHbUQ4SkkycU9OWlVtYko4SnJ0ejZDRk5ZYVBUVkkzclRtYVd1SUVuZFVkRHpmNjFDZ0hnRVZoSk1VdDVtNzBsV1lYcFFpRFdkWXY5NTF1WUw2UjJURHFkOHExekJnNU11OUNfc3VyVDRXRjFDSDAwLTg3MW45NjJDeklEOS1iZHZkbDhuSg?oc=5","date":"2026-02-04","type":"earnings","source":"GlobeNewswire","summary":"Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th - GlobeNewswire","headline":"Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th","sentiment":"neutral"},{"date":"2025-12-17","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2025-12-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-10-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-08","type":"pipeline","source":"simplywall.st","summary":"Veru Inc.'s (NASDAQ:VERU) Share Price Boosted 29% But Its Business Prospects Need A Lift Too - simplywall.st","headline":"Veru Inc.'s (NASDAQ:VERU) Share Price Boosted 29% But Its Business Prospects Need A Lift Too","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-23","type":"regulatory","source":"GlobeNewswire","summary":"Veru Announces Successful FDA Meeting Providing Regulatory - GlobeNewswire","headline":"Veru Announces Successful FDA Meeting Providing Regulatory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPWDl5VDRSMTg5VVJucWNIYnZIckgwZWpYU0FGdFFSVWhTeWkxdThQUVl3T09OclFESElmWWRWVzczNHNDMG5HaUxiWnZpcC1xOFhLT1paUE1vRW9VaUtzVjZlS21YclQ4cDhiTFgtWXhnMDhzUDlwc3FURnJWQWo5LXNsMGVoU011R1B3MXFR?oc=5","date":"2025-08-11","type":"trial","source":"Yahoo Finance","summary":"Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study - Yahoo Finance","headline":"Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Followi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOWmlKdXRSWjU1SjJlTzh4WEZiNWhhd2VZU28tZFBaZGdhNW1hVnFRWjFtbjgxMDl6cnc5dnhiQ3U5Y0hrWVVQblJmX0ZCTWNTODRMSW83VkstMmpNcWtaOTZJblBKSXJHWXN4em9FMnhnNzEtLWZfcC1qSGo5bDRDbFpqVzF6bU5US3RpYkFKS1lpZUU?oc=5","date":"2025-08-11","type":"pipeline","source":"Yahoo Finance","summary":"Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru’s Enobosarm, Utilizing Laxxon’s SPID®-Technology - Yahoo Finance","headline":"Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru’s","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOVFhVSGJOX2lQM0lsM0lmYk9kcmNIbnBLYVhnTE5fQ0JIb25PYzBseHBPeHBLTTJVRU5KNkhCcWV0S0FZVW1MSFI0X3Rsa2wteFN2SXZEdWVEM29iSjR2a21ESS0tVmVWc0NxaXNVWGI5WllpSDRhRUJ6VDdsLTZ0dDF3T0hwOVZvdWd4SV9HVzl1NUE4OWxiLUFYOFpfZ1dJSWlFSFJoMXZhNmJZRlNn?oc=5","date":"2025-08-06","type":"pipeline","source":"GlobeNewswire","summary":"Veru Announces Reverse Stock Split - GlobeNewswire","headline":"Veru Announces Reverse Stock Split","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxObS1mTmQ5WEtHZ29haG5uOFdrSHFBa05iMnNISl8zNkdhZFpvSmwybVNyNzZPVUVnbjRKRmxhdzVTTWxVWTZBU0ptR084ZkpiZHJUYjhibzVnVW9MSUtpOGJoeXg4UU5lRHZSUFc3QXItSG5kb0JTUk9jSEV4d1V0Q3puMzVkTkg4QlRJc3FFOGU?oc=5","date":"2025-05-28","type":"trial","source":"BioPharma Dive","summary":"Muscle-sparing obesity drug safe for Phase 3 trial, Veru says - BioPharma Dive","headline":"Muscle-sparing obesity drug safe for Phase 3 trial, Veru says","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOVHhNc21LZkVOSjFIWFFmZ1FfUkQ0UHdrcjFlb1h2Z2hzdTVQNUtoM1p5b2ZGdEpLaGp2SEE2ckp2dEd6RVVUTGFrMGZDa3dKSnNZU2tqUEVlUXRpTFBqdnFtTG9FUmRmNWVKLWJYaW9RS0VPQU16N3NKWnpzTFN6XzZDSllGZmVIN1BzYmlxdU1CSnFES2xrQ19BZnZidw?oc=5","date":"2025-05-26","type":"pipeline","source":"Seeking Alpha","summary":"Veru: Saving Muscle Mass Amidst The GLP-1 Drug Boom - Seeking Alpha","headline":"Veru: Saving Muscle Mass Amidst The GLP-1 Drug Boom","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOZXl6Zm8xdHBKb3VyM3dLT0FXME1KYlpJSUd6T0pNSnhEUGkzR3dlbHJMOEhXenNpM3lGRDB1TDl2UE55eGI0b3RRNE8xS0JNbWdvSGpVSWttcjZEaTVPeDhhRFJBSTZybzBsX0o2MzVNUWliN3FNajNpanQ4WlB6RHZ5dTRnVTRxbEl2Yg?oc=5","date":"2025-01-28","type":"trial","source":"pharmaphorum","summary":"Veru shares plunge despite positive data in obesity trial - pharmaphorum","headline":"Veru shares plunge despite positive data in obesity trial","sentiment":"positive"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":16296958,"revenuePeriod":"2023-09-30","revenueHistory":[{"value":16296958,"period":"2023-09-30"},{"value":39354352,"period":"2022-09-30"},{"value":39354352,"period":"2022-09-30"},{"value":61259528,"period":"2021-09-30"},{"value":61259528,"period":"2021-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":15588185,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-22726279,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":29835719,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}